Advanced systemic mastocytosis is a progressive condition characterized by the accumulation of mast cells in the body’s organs. There’s no cure for advanced systemic mastocytosis, but many of the ...

Q: Which doctor should I consult for mastocytosis? A: You should consult your family physician when you notice symptoms of rash or other allergy on your skin or breathlessness and diarrhea. Based on ...

Avapritinib (Ayvakit, Blueprint Medicines), a novel agent that targets a specific mutation found in 90% of patients with systemic mastocytosis, reduces skin lesions and mast cell burden, according to ...

Systemic mastocytosis is a myeloid neoplasm divided into six subcategories by the recent classification by WHO. It involves the accumulation of abnormal mast cells (MCs) in the skin, liver, spleen, ...

A diagnosis of advanced systemic mastocytosis (advSM), a rare blood disorder in which too many mast cells accumulate in various parts of the body, can cause a range of strong emotions. AdvSM sometimes ...

A standard treatment for mastocytosis is difficult to apply to individual patients based on the variable clinical course. A general consensus for using antimediator agents such as antihistamines, ...

Aberrant expression of CD2 and/or CD25 by bone marrow, peripheral blood or other extracutaneous tissue mast cells is currently used as a minor World Health Organization diagnostic criterion for ...

Cogent Biosciences, Inc. (NASDAQ:COGT) is among the 20 Best Performing Stocks in 2025. Based on a research note dated January ...

New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

After a median treatment duration of 10.5 months (range, 2 to 32) and a median follow-up of 18.5 months (range, 3 to 36), the overall response rate in the midostaurin group was 71%, which included a ...

Cogent Biosciences (COGT) has filed a New Drug Application with the FDA for bezuclastinib in NonAdvanced Systemic Mastocytosis, following positive SUMMIT trial results that met all primary and key ...